Stable measurement of chemistry, immunochemistry, and hematology analytes in a heparin‐based anticoagulant with iloprost additive: A promising candidate for the polyvalent blood collection tube

Abstract

AbstractIntroductionA polyvalent blood collection tube could potentially reduce the number and volume of blood samples drawn from patients and reduce the risk of tube mix‐ups in a point‐of‐care setting in the emergency department and the intensive care unit.MethodsFour different concentrations of our experimental heparin anticoagulant with iloprost additive (HEP‐ILOP 50 nM, 150 nM, 1000 nM, and 10 μM, respectively) were tested for significant differences and bias performance specifications against EDTA for 29 hematology analytes, and the highest concentration (HEP‐ILOP 10 μM) against lithium heparin for 14 chemistry and immunochemistry analytes. Samples were drawn from 79 consenting subjects from the Oncology Department (n = 38) and the Intensive and Intermediary Care Unit (n = 41).ResultsFor hematology analytes, the HEP‐ILOP formulation generally provided stable measurement within optimal requirements within 5 h after sampling (mean 104 ± 56 min), with very little difference between the four HEP‐ILOP concentrations. Because of differences in platelet and red blood cell swelling between EDTA and HEP‐ILOP, all size‐dependent analytes required proportional factorization to produce similar results. Platelet count by impedance similarly required factorization, whereas the fluorescent method provided results identical with EDTA. Chemistry and immunochemistry analytes were within optimal requirements except for potassium, lactate dehydrogenase, and glucose, indicating a cytoprotective effect of iloprost reducing cell metabolism and rupture, thereby producing results closer to in vivo conditions.ConclusionsOur novel dry‐sprayed anticoagulant formulation, HEP‐ILOP, is a promising candidate for a polyvalent blood collection tube, enabling the analysis of hematology, chemistry, and immunochemistry analytes in the same tube.